DRP-104
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for DRP-104, covering 2025-11-25 to 2026-02-24. Get the full timeline:
Most recent: Clinical Trial Update: A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) [Phase 1]